CRISPR Therapeutics (CRSP)

Executive Summary

CRISPR Therapeutics is a leading gene-editing biopharmaceutical company focused on developing transformative therapies for serious diseases using its CRISPR/Cas9 platform. The company's most advanced program, exagamglogene autotemcel (exa-cel), developed in collaboration with Vertex Pharmaceuticals, targets transfusion-dependent beta thalassemia and severe sickle cell disease. Exa-cel has received regulatory approvals in multiple regions, including the U.S. and EU, and is now expanding into new markets. Beyond hemoglobinopathies, CRISPR Therapeutics is advancing a pipeline of allogeneic CAR-T cell therapies, including CTX112 for B-cell malignancies and systemic lupus erythematosus (SLE), and CTX131 for solid tumors. The company's fully integrated R&D and manufacturing infrastructure, combined with strategic partnerships, positions it as a leader in gene editing. With a strong cash position and multiple clinical catalysts ahead, CRISPR Therapeutics is poised for continued growth.

Upcoming Catalysts (preview)

• H2 2026Exa-cel regulatory approval in China and other key markets80% success
• Q1 2027Phase 1/2 interim data readout for CTX112 in SLE60% success
• H1 2027Initial efficacy data from Phase 1/2 trial of CTX131 in solid tumors55% success